Jeligo

Linagliptin, the active ingredient in Jeligo, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients, helping to lower blood glucose levels when combined with diet and exercise.

GNH USA supplies Jeligo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation.

- Type 2 diabetes mellitus: improves glycemic control when used with diet and exercise. - Inadequate control on metformin alone: adds DPP‑4 inhibition to further lower HbA1c. - Combination therapy with other antidiabetic agents: enhances overall glucose management.

Linagliptin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Headache: transient tension‑type headaches. - Nasopharyngitis: upper respiratory tract infection symptoms. - Dizziness: occasional light‑headedness. - Arthralgia: joint pain without swelling. - Diarrhea: loose stools that resolve spontaneously.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated transaminases or jaundice. - Bullous pemphigoid: blistering skin disorder. - Angioedema: swelling of face, lips, or throat. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal impairment: assess kidney function; dose may need adjustment. - Hepatic impairment: use with caution; monitor liver enzymes. - Concurrent insulin or sulfonylureas: increased risk of hypoglycemia; consider dose reduction. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Elderly patients: monitor for adverse effects due to polypharmacy. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Insulin secretagogues (e.g., sulfonylureas): heightened hypoglycemia risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Rifampin (CYP inducer): may reduce linagliptin efficacy.

Moderate Interactions (Monitor Closely):\n- Diuretics: possible alteration of glucose control. - ACE inhibitors: monitor renal function and electrolytes. - Warfarin: periodic INR checks recommended.